Directorate Change

GlaxoSmithKline PLC
06 February 2006

Issued - Monday 6 February 2006, London





Dr. Moncef Slaoui to Head GlaxoSmithKline Research and Development





GlaxoSmithKline plc (GSK) has announced today that Dr. Moncef Slaoui, currently
Senior Vice President, Worldwide Business Development and External Alliances,
GSK R&D, will become Chairman, Research & Development, effective 1st June 2006.
Reporting to Dr. Jean-Pierre Garnier, Chief Executive Officer of GSK, Dr. Slaoui
will also join the Corporate Executive Team and the company's Board of
Directors.



Dr. Slaoui, 46, will succeed Dr. Tadataka (Tachi) Yamada, who will retire from
the company on 1st June to become Executive Director of the Global Health
Program at the Bill & Melinda Gates Foundation. The retirement of Dr. Yamada is
the subject of a separate announcement today.



Dr. Slaoui will bring to his new role broad experience in scientific research,
product development, and executive management. In his current position, he has
served on the R&D Executive Team and spearheaded recent changes in R&D to
enhance drug discovery and accelerate product development. Previously, in GSK
Biologicals, he engineered the development of a robust vaccines pipeline,
including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to
prevent cervical cancer.



"Moncef combines scientific acumen, sound business sense, and a fervent
commitment to public health," said Dr. Garnier. "Following a career in academia,
he has demonstrated during his 17 years at GSK that he can create a strategic
vision and then vigorously pursue it to develop new products that profoundly
enhance healthcare."



"Moncef is an outstanding scientist and a charismatic leader.  Most importantly
he and I share a common commitment to the welfare of patients," said Dr. Yamada.



Dr. Slaoui said, "GSK has one of the most promising pipelines in the industry.
Our challenge, going forward, is to deliver to patients the many medicines we
have in development, whilst continuing to grow the pipeline.  Along with my
colleagues in R&D, we are embracing this challenge and we fully expect to be
able to deliver medicines of great value for patients and for GSK in the coming
years."



Dr. Slaoui earned a Ph.D. in Molecular Biology and Immunology from the
Universite Libre de Bruxelles, Belgium, and completed postdoctoral studies at
Harvard Medical School and Tufts University School of Medicine, Boston. He was a
professor of Immunology at the University of Mons, Belgium. He has authored more
than 100 scientific papers and presentations. A citizen of Morocco and Belgium,
he is fluent in English, French, and Arabic.



S M Bicknell

Company Secretary



6 February 2006








Enquiries:

UK Media enquiries:                      Philip Thomson          [phone]
                                         David Mawdsley          [phone]
                                         Chris Hunter-Ward       [phone]
                                         Alice Hunt              [phone]

US Media enquiries:                      Nancy Pekarek           [phone]
                                         Mary Anne Rhyne         [phone]
                                         Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:     Duncan Learmouth        [phone]
                                         Anita Kidgell           [phone]
                                         Jen Hill                [phone]

US Analyst/ Investor enquiries:          Frank Murdolo           [phone]
                                         Tom Curry               [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange